205 related articles for article (PubMed ID: 25244504)
1. Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
Paland N; Gamliel-Lazarovich A; Coleman R; Fuhrman B
Atherosclerosis; 2014 Nov; 237(1):200-7. PubMed ID: 25244504
[TBL] [Abstract][Full Text] [Related]
2. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator downregulates paraoxonase 1 expression in hepatocytes by stimulating peroxisome proliferator-activated receptor-γ nuclear export.
Khateeb J; Kiyan Y; Aviram M; Tkachuk S; Dumler I; Fuhrman B
Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):449-58. PubMed ID: 22155455
[TBL] [Abstract][Full Text] [Related]
4. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator (uPA) decreases hepatic SR-BI expression and impairs HDL-mediated reverse cholesterol transport.
Chulsky S; Paland N; Lazarovich A; Fuhrman B
Atherosclerosis; 2014 Mar; 233(1):11-8. PubMed ID: 24529115
[TBL] [Abstract][Full Text] [Related]
6. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
7. Activation of PPARalpha and PPARgamma reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1.
König B; Koch A; Spielmann J; Hilgenfeld C; Hirche F; Stangl GI; Eder K
Eur J Pharmacol; 2009 Mar; 605(1-3):23-30. PubMed ID: 19248225
[TBL] [Abstract][Full Text] [Related]
8. Urokinase induces stromal cell-derived factor-1 expression in human hepatocellular carcinoma cells.
Hsu WH; Chen CN; Huang HI; Lai YL; Teng CY; Kuo WH
J Cell Physiol; 2012 Feb; 227(2):697-704. PubMed ID: 21465475
[TBL] [Abstract][Full Text] [Related]
9. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
[TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner.
Fuhrman B; Nitzan O; Karry R; Volkova N; Dumler I; Aviram M
Atherosclerosis; 2007 Dec; 195(2):e108-16. PubMed ID: 17681345
[TBL] [Abstract][Full Text] [Related]
11. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
13. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism.
Fuhrman B; Khateeb J; Shiner M; Nitzan O; Karry R; Volkova N; Aviram M
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1361-7. PubMed ID: 18436804
[TBL] [Abstract][Full Text] [Related]
14. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
15. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
17. Coordinated alteration of hepatic gene expression in fatty acid and triglyceride synthesis in LCAT-null mice is associated with altered PUFA metabolism.
Song H; Zhu L; Picardo CM; Maguire G; Leung V; Connelly PW; Ng DS
Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E17-E25. PubMed ID: 16105858
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.
Jin K; Norris K; Vaziri ND
Nephrol Dial Transplant; 2013 Feb; 28(2):313-20. PubMed ID: 23045433
[TBL] [Abstract][Full Text] [Related]
19. DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER.
Rong S; Xia M; Vale G; Wang S; Kim CW; Li S; McDonald JG; Radhakrishnan A; Horton JD
Cell Metab; 2024 Mar; 36(3):617-629.e7. PubMed ID: 38340721
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
